Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11513/133
Başlık: New prognostic biomarker in cardiovascular field: ST2 (IL1RL1)
Yazarlar: Dikme, Reşat
Padak, Mahmut
Göz, Mustafa
Aydın, Mehmet Salih
Göç, Ömer
Anahtar kelimeler: ST2; Interleukin 1 Receptor-Like 1; sST2; Soluble sST2; Cardiovascular Diseases; IL1RL1
Yayın Tarihi: 2019
Yayıncı: The Annals of Clinical and Analytical Medicine
Özet: As a result of natural immunity in the heart ST2 (IL1RL1) that protects the heart against excessive pressure load and tension, has two important isoforms (ST2L–membranebound, sST2-soluble). As ligand of ST2L and sST2 is interleukin 33 (IL33), the connection of ST2L to IL33 stimulates cardioprotective signal cascade whereas connection of sST2 to IL33 causes annihilation of these positive effects. As a high level of sST2 shows that the heart is under dense stress, this situation causes cell death, tissue fibrosis, decreased cardiac functions and an increase in progression rate of disease. That is why in cardiovascular disease sST2 is accepted as a biomarker of poor prognosis. It was obtained that the increase of sST2 over normal concentration multiplies negative situations related to cardiovascular diseases 3 times more. In 2013 in ACCF/AHA (American College of Cardiology Foundation/American Heart Association) guidelines, sST2 that was defined as “novel biomarker” for HF (Heart failure), is an independent biomarker from natriuretic peptides and cardiac troponins and is an important sign in cardiovascular diseases. ST2 is not affected by factors such as age, body mass index and kidney function disorder.
URI: http://hdl.handle.net/11513/133
Koleksiyonlarda Görünür:Perfüzyonistlik Bölümü

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
New prognostic biomarker in cardiovascular field ST2 (IL1RL1).pdf558.61 kBAdobe PDFGöster/Aç


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.